Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21532415 | 0.95 | KDM4E (0.39) | KDM4EATML3MBTL1AVPR1ASMN1; SMN2 | |
| SCHEMBL21532797 | 0.94 | AKT1 (0.38) | KDM4EATML3MBTL1AVPR1ASMN1; SMN2 | |
| SCHEMBL21532734 | 0.93 | KDM4E (0.40) | KDM4EATML3MBTL1AVPR1ASMN1; SMN2 | |
| SCHEMBL21532581 | 0.92 | KDM4E (0.39) | KDM4EATML3MBTL1AVPR1ASMN1; SMN2 | |
| SCHEMBL21532451 | 0.91 | AKT1 (0.38) | KDM4EATML3MBTL1AVPR1ASMN1; SMN2 | |
| SCHEMBL21532263 | 0.91 | KDM4E (0.36) | KDM4EATML3MBTL1AVPR1ASMN1; SMN2 | |
| SCHEMBL21532514 | 0.90 | AKT1 (0.38) | KDM4EATML3MBTL1AVPR1ASMN1; SMN2 | |
| SCHEMBL21532622 | 0.90 | AKT1 (0.38) | KDM4EATML3MBTL1AVPR1ASMN1; SMN2 | |
| SCHEMBL21532461 | 0.90 | AVPR1A (0.40) | KDM4EATML3MBTL1AVPR1ASMN1; SMN2 | |
| SCHEMBL21532719 | 0.89 | KDM4E (0.40) | KDM4EATML3MBTL1AVPR1ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11145825-B2 | Condensed cyclic compound and organic light-emitting device including i he same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2021-10-12 | — | — | US | disclosed |
| US-20190334095-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11145825-B2 | Condensed cyclic compound and organic light-emitting device including i he same | CRY1, CCNT1, CCNA1 | KDM4E 4144/4885ATM 622/4885L3MBTL1 370/4885 |
| US-20190334095-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CCNT1, ARL1 | KDM4E 3893/4885ATM 368/4885L3MBTL1 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.